Opus Genetics (IRD) — Scientific Deep Dive for OPGx-LCA5, OPGx-BEST1, and the IRD Gene Therapy Pipeline
The String-of-Pearls in Ophthalmology: Real Clinical Proof-of-Concept Wrapped in Ultra-Orphan Math and a Warrant-Heavy Balance Sheet
Executive Summary
The Hook. Opus is building a portfolio of AAV (adeno-associated virus) gene-augmentation therapies for monogenic inherited retinal diseases (IRDs), riding the Luxturna playbook into genes nobody else is chasing — and it now has human functional-vision data in two of them.
The Bull Case. Two clinical assets have shown genuine signal. OPGx-LCA5 improved visual acuity and retinal sensitivity in 5 of 6 patients with durability to 18 months, earned RMAT (Regenerative Medicine Advanced Therapy), Orphan, Rare Pediatric Disease, and acceptance into the FDA’s Rare Disease Evidence Principles (RDEP) pilot — a combination that points toward approval on a small dataset plus a Priority Review Voucher (PRV) worth ~$100–150M on issuance. OPGx-BEST1’s sentinel patient gained 12 ETDRS letters with a 23% reduction in central retinal thickness at three months, and BEST1 addresses ~22,000 patients globally — roughly 7x the LCA5 population. Behind them sit five more programs, worldwide rights to all of them, and a smart-money register led by Perceptive Advisors (9.99%) and Nantahala. If LCA5 reaches market and BEST1 confirms, this is a rare-disease platform with multiple shots on goal and obvious strategic-acquirer appeal.
The Bear Case. The addressable populations are minuscule. LCA5 is ~170 U.S. patients; even at Luxturna’s $850,000 price the entire U.S. one-time TAM is ~$150M, and Luxturna’s own commercial history (modest sales despite the price) shows ultra-orphan ophthalmology does not print money. The efficacy datasets are N=6 (LCA5) and N=1 sentinel (BEST1), open-label, with fellow-eye “controls” and effort-dependent functional endpoints — exactly the setup where “5 of 6” can regress. Nearly all composition-of-matter IP is in-licensed (Penn, University of Florida, Iveric) with stacked milestones and royalties and, for BEST1, the core composition-of-matter family is still pending, not granted. The capital structure carries 22.9M liability-classified warrants, 16.0M pre-funded warrants, and a new $155M Oberland secured-debt facility with an all-asset lien and a down-round ratchet — and the stock has already 7x’d off its lows. Mission holder Foundation Fighting Blindness sold below 5% in May 2026.
